A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

Inclusion Criteria:

1. Previous, documented diagnosis of hypertension, or newly diagnosed hypertensionaccording to the fourth report on the diagnosis, evaluation and treatment of highblood pressure in children and adolescents (United States). SiSBP greater than orequal to the 95th percentile for age, gender, and height.

2. The subject can be safely withdrawn from antihypertensive medications during thescreening period, and if given placebo during the treatment period in the judgment ofthe Investigator.

3. The subject is male or female age 6 to 16 years (inclusive), and weighs greater thanor equal to 20 kg.

4. Female subjects greater than or equal to 12 years of age, or who have had greater thanor equal to 1 menstruation must: (a) have a negative serum pregnancy test at screening (i.e., subject is not pregnant), (b) not be lactating, and (c) use an acceptablemethod of contraception.

5. Parents/guardians are able to demonstrate their ability to (a) use a home bloodpressure monitor supplied for the study to monitor their child's blood pressure, and (2) mix and administer a liquid dose of study drug if needed.

Exclusion Criteria:

1. Bilateral renal artery stenosis.

2. Uncorrected coarctation of the aorta or corrected coarctation with a right arm/rightleg blood pressure gradient greater than 10 mmHg.

3. Severe hypertension.

4. Renal transplantation or other previous solid organ transplantation less than 6 monthsprior to entering the study.

5. Subjects with nephrotic syndrome not on stable maintenance therapy of prednisone orcyclosporine.

6. A history of cardiomyopathy, clinically significant structural heart disease, oratrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrialfibrillation, clinically significant bradycardia or an accessory bypass tract, orclinical symptoms of congestive heart failure.

7. Clinically significant hematologic, hepatobiliary, or renal disease including aSchwartz formula GFR less than 40 mL/min/1.73 m2, and/or serum potassium (K+) greaterthan 5.5 mEq/L.

8. History of pancreatitis (active or inactive).

9. Known sensitivity to angiotensin converting enzyme inhibitors or a history ofangioneurotic edema.